News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
The organizations provided a list of genes they believe are informative in treatment of myeloid disorders and suggested several changes to the coverage policy.
The test is designed to determine whether a patient with a pelvic mass is at high risk of having ovarian cancer and should be referred for surgery.
Under the determination, which will become final following publication in Germany's Federal Gazette, Oncotype DX becomes the only multigene test nationally reimbursed in Germany for its target population early-stage breast cancer patients.
